Sep. 10 at 12:19 PM
$SLN CEO Craig Tooman: Lead drug for rare blood cancer PV (polycythemia vera) in Phase II, data due H2 2026. siRNA platform shows strong efficacy (0 phlebotomies in controlled pts).
$114M cash into 2028. Seeking partner for Lp(a) cardio program (
$300M+ trial). 🧬 #Biotech #Investing